ΒΆ IL-6
Type: Cytokine / Myokine
Source: Leukocytes, Adipocytes, endothelial cells, muscle
Receptors: IL-6R (membrane-bound), sIL-6R (soluble), gp130
Pathways: JAK/STAT3, MAPK, PI3K
Systems: Immune, Neuro, Metabolism, Musculoskeletal
ΒΆ Definition
Interleukin-6 (IL-6) is a 21-26 kDa pleiotropic cytokine with context-dependent pro- and anti-inflammatory properties, produced by leukocytes, Adipocytes, endothelial cells, and contracting muscle fibres during physical activity. It signals through two distinct pathways: classic signalling via membrane-bound IL-6R (predominantly anti-inflammatory and regenerative) and trans-signalling via soluble IL-6R (sIL-6R, predominantly pro-inflammatory), allowing the same molecule to orchestrate both metabolic health and chronic disease depending on source, duration, and cellular context.
ΒΆ Picture It
IL-6 is like a fire truck siren β the exact same sound produces completely different responses depending on where it comes from and how long it lasts. When the siren comes from your neighbourhood gym (muscle-derived IL-6 during exercise), it's a brief, organized response: traffic clears, glucose trucks rush to delivery points, fat storage warehouses open their doors, and anti-inflammatory cleanup crews (IL-10) mobilize for repair work. Everyone goes home after 2-4 hours, leaving the streets cleaner than before. But when the siren comes from the chronic industrial fire at the fat factory (adipose-derived IL-6 in obesity), it never stops. The constant wailing triggers the liver to dump emergency supplies (acute phase proteins), activates the stress headquarters (HPA axis), blocks insulin delivery routes, and creates inflammation that spreads to the brain's command centre (insular cortex). The cleanup crews give up. Traffic patterns change permanently. What should have been a helpful 2-hour alert becomes a 24/7 crisis that nobody can resolve β same siren, opposite outcomes. The key difference? Exercise IL-6 goes through the front door (membrane IL-6R on cells that need it), while chronic IL-6 breaks in through every window (soluble IL-6R allowing any cell to respond).
ΒΆ Mechanism
IL-6 signals through two mechanistically distinct pathways with opposite physiological consequences:
Classic Signalling (Anti-inflammatory/Regenerative):
- IL-6 binds membrane-bound IL-6R (CD126) β IL-6/IL-6R complex recruits two gp130 (CD130) molecules β hexameric complex formation
- gp130 dimerization activates JAK1, JAK2, and TYK2 tyrosine kinases β phosphorylate gp130 intracellular domain
- Phosphorylated gp130 recruits STAT3 β JAK phosphorylates STAT3 at Tyr705 β STAT3 homodimerization β nuclear translocation
- Nuclear STAT3 binds DNA response elements β transcription of IL-10, IL-1RA, SOCS3, BCL-2, MCL-1
- Parallel activation: gp130 β SHP2 β RAS β RAF β MEK β ERK1/2 (MAPK pathway) β c-FOS, c-JUN transcription
- Third pathway: gp130 β PI3K β AKT β mTOR β protein synthesis, glucose uptake via GLUT4 translocation
Trans-Signalling (Pro-inflammatory/Pathogenic):
- IL-6 binds soluble IL-6R (sIL-6R, generated by ADAM10/ADAM17 proteolytic cleavage or alternative splicing) β IL-6/sIL-6R complex
- Complex binds gp130 on cells lacking membrane IL-6R (vascular endothelium, neurons, fibroblasts) β same JAK/STAT3 activation
- Trans-signalling preferentially activates: STAT3 β NF-ΞΊB β IL-8, VEGF, ICAM-1, MCP-1 transcription
- Hepatocytes respond to IL-6/sIL-6R β STAT3 β acute phase protein genes (CRP, SAA, fibrinogen, haptoglobin)
- Hypothalamic neurons respond β STAT3 β SOCS3 β leptin resistance β hyperphagia
- Adipocytes respond β STAT3 β lipolysis inhibition, insulin receptor substrate-1 (IRS-1) serine phosphorylation β insulin resistance
Muscle-Derived IL-6 During Exercise:
- Muscle contraction β calcium release β calcineurin activation β NFAT β IL-6 gene transcription
- Glycogen depletion β AMPK activation β p38 MAPK β ATF-2 β IL-6 promoter activation
- IL-6 secretion increases 100-fold (baseline ~1-5 pg/mL β peak 50-500 pg/mL at exercise end)
- Autocrine effects on muscle: IL-6 β AMPK activation β glucose uptake (insulin-independent), fatty acid oxidation
- Paracrine effects: IL-6 β liver glycogenolysis, adipose lipolysis, pancreatic insulin secretion
- Systemic effects: IL-6 β hypothalamus β CRH release β ACTH β cortisol (metabolic coordination)
- Post-exercise: IL-6 β monocytes/macrophages β IL-10 release β suppression of TNF-Ξ±, IL-1Ξ²
ΒΆ Clinical Significance
IL-6 exemplifies the context-dependent nature of immune signalling central to cPNI β the same molecule drives metabolic health or disease depending on cellular source, signalling mode, and temporal pattern. This maps directly to Metamodel 4 (5 plus 2 metamodel): exercise-induced IL-6 represents Intermittent Living creating metabolic resilience, while adipose-derived chronic IL-6 represents the low-grade inflammation pattern of metabolic disease.
Exercise as Medicine Mechanism: Muscle-derived IL-6 during physical activity explains why movement is anti-inflammatory despite raising a "pro-inflammatory" cytokine. The transient 100-fold spike (returning to baseline within 2-4 hours) triggers IL-10 release, enhances insulin-independent glucose uptake via GLUT4, and promotes fat oxidation through AMPK activation. This is hormetic signalling β brief stress creating adaptation.
Chronic Disease Driver: Sustained elevation from adipose tissue (especially visceral fat) drives the Selfish immune system pattern: IL-6 β Liver β acute phase proteins (C-reactive protein >3 mg/L, fibrinogen, Serum amyloid A) β systemic inflammation β insulin resistance via SOCS3 and IRS-1 serine phosphorylation. IL-6 >10 pg/mL predicts cardiovascular events and all-cause mortality independent of other risk factors.
Brain-Immune Integration: IL-6 crosses the blood-brain barrier via saturable transport, reaching the insular cortex where it generates immunoceptive signals interpreted as fatigue, malaise, pain amplification, and depressed mood. This explains the co-occurrence of Depression, chronic pain, and chronic fatigue syndrome β all show elevated IL-6 (typically 5-15 pg/mL). Treatment-resistant depression specifically correlates with IL-6 >3 pg/mL.
Trans-Signalling as Disease Amplifier: Soluble IL-6R (sIL-6R) allows cells without membrane IL-6R to respond, creating pathological inflammation in vascular endothelium (atherosclerosis), synovium (rheumatoid arthritis), and brain (neuroinflammation). The sgp130 (soluble gp130) acts as natural trans-signalling inhibitor β therapeutic sgp130-Fc fusion proteins selectively block pathogenic trans-signalling while preserving beneficial classic signalling.
Clinical Interventions:
- Movement prescription: 150+ minutes/week moderate activity generates beneficial IL-6 pulses; vigorous intermittent lifestyle physical activity (VILPA) creates stronger signals
- Adiposity reduction: Each 1 kg visceral fat loss reduces baseline IL-6 ~0.3 pg/mL
- Anti-inflammatory nutrients: Omega-3 (EPA/DHA) reduces IL-6 production; Curcumin inhibits NF-ΞΊB β IL-6 gene transcription
- Biological therapy: Tocilizumab (anti-IL-6R antibody) effective in rheumatoid arthritis, giant cell arteritis, COVID-19 cytokine storms β but may block exercise benefits if used chronically
- Resolvin enhancement: Specialized pro-resolving mediators (SPMs) like RvD1 actively resolve IL-6-driven inflammation without immunosuppression
Key Clinical Threshold: IL-6 
pg/mL = metabolic health; 3-10 pg/mL = chronic low-grade inflammation zone; >10 pg/mL = high mortality risk. Exercise-induced transient spikes to 50-500 pg/mL are therapeutic, not pathogenic.
ΒΆ Key Facts
- Dual signalling modes: Classic (membrane IL-6R, anti-inflammatory) vs trans-signalling (soluble IL-6R, pro-inflammatory)
- Exercise response: Muscle-derived IL-6 increases 100-fold during physical activity (from ~2 pg/mL to 50-500 pg/mL), peaks at exercise cessation, returns to baseline within 2-4 hours
- Chronic elevation thresholds: >3 pg/mL associated with metabolic disease; >5 pg/mL predicts type 2 diabetes; >10 pg/mL predicts mortality
- Depression biomarker: Elevated in 30-50% of MDD patients (typically 5-15 pg/mL); levels >3 pg/mL predict SSRI treatment resistance
- Acute phase orchestrator: Primary inducer of hepatic C-reactive protein (1 pg/mL IL-6 β ~0.5 mg/L CRP increase), fibrinogen, serum amyloid A, haptoglobin
- Brain access: Crosses blood-brain barrier via saturable transport (Km ~800 pg/mL); reaches insular cortex generating fatigue, pain amplification, mood symptoms
- Metabolic regulator: Muscle IL-6 increases insulin-independent glucose uptake 2-3 fold via AMPK β GLUT4 translocation; simultaneously increases hepatic glucose output
- Insulin resistance mechanism: Chronic IL-6 induces SOCS3 β blocks insulin receptor signaling; phosphorylates IRS-1 at serine residues β impaired PI3K activation
- Anti-inflammatory mediator: Exercise-induced IL-6 stimulates IL-10 production (5-10 fold increase) and IL-1 receptor antagonist, suppressing TNF-Ξ± and IL-1Ξ²
- Adipose source: Visceral adipose tissue contributes 15-35% of circulating IL-6 in obesity (vs <5% in lean individuals); subcutaneous fat contributes less
- COVID-19 severity: IL-6 >80 pg/mL predicts severe disease; >200 pg/mL predicts mortality; tocilizumab reduces deaths in severe cases
- Lifespan marker: Each 1 pg/mL increase in baseline IL-6 associated with 15% increase in all-cause mortality over 10 years
ΒΆ Connections
- Myokines β IL-6 is the archetypal exercise-induced myokine, accounting for majority of contraction-induced cytokine release from muscle
- physical activity β contracting muscle releases IL-6 proportional to exercise intensity, duration, and muscle glycogen depletion
- AMPK β both activated by muscle IL-6 (via CaΒ²βΊ and metabolic stress) and regulates IL-6 gene expression via p38 MAPK pathway
- GLUT4 β muscle-derived IL-6 enhances insulin-independent glucose uptake via AMPK-mediated GLUT4 translocation to sarcolemma
- IL-10 β exercise-induced IL-6 stimulates monocyte IL-10 production, creating anti-inflammatory environment post-exercise
- C-reactive protein β hepatic CRP production directly proportional to circulating IL-6; CRP >3 mg/L typically reflects IL-6 >5 pg/mL
- acute phase response β IL-6 is primary orchestrator of hepatic acute phase protein synthesis via STAT3 activation
- insular cortex β IL-6 reaches anterior insula generating immunoceptive signals: fatigue perception, pain amplification, negative mood
- Depression β elevated in 30-50% of MDD patients; correlates with treatment resistance, anhedonia, and psychomotor retardation
- chronic fatigue syndrome β consistently elevated IL-6 (5-12 pg/mL) correlates with fatigue severity and post-exertional malaise
- obesity β visceral adipose tissue major IL-6 source in obesity; adipocyte hypertrophy β hypoxia β HIF-1Ξ± β IL-6 transcription
- insulin resistance β chronic IL-6 induces SOCS3 blocking insulin signaling; phosphorylates IRS-1 serine residues impairing PI3K activation
- cardiovascular disease β IL-6 >3 pg/mL predicts myocardial infarction, stroke; drives endothelial dysfunction via trans-signalling
- JAK-STAT pathway β IL-6 signals primarily via JAK1/JAK2/TYK2 β STAT3 Tyr705 phosphorylation β nuclear translocation
- TNF-Ξ± β synergistic pro-inflammatory effects; TNF primes cells for IL-6 response; both elevated in metabolic syndrome
- IL-1Ξ² β upstream inducer of IL-6 (IL-1Ξ² β NF-ΞΊB β IL-6 gene); inflammasome activation amplifies IL-6 release
- neuroinflammation β IL-6 activates microglia, induces astrocyte reactivity, disrupts blood-brain barrier tight junctions
- rheumatoid arthritis β synovial IL-6 drives pannus formation, osteoclast activation, systemic symptoms; tocilizumab highly effective
- COVID-19 β SARS-CoV-2 infection β IL-6-driven cytokine storm; IL-6 blockade reduces mortality in severe cases
- HPA axis β IL-6 stimulates hypothalamic CRH release β ACTH β cortisol; chronic elevation drives cortisol resistance
- cognitive dysfunction β elevated IL-6 associated with hippocampal atrophy, reduced neurogenesis, dementia risk
- Liver β hepatocytes are primary responders to circulating IL-6; produce acute phase proteins, glucose, and IGF-binding proteins
- Adipocytes β visceral adipocytes major IL-6 source in obesity; adipocyte IL-6 drives local and systemic insulin resistance
- NF-ΞΊB β transcription factor activated by IL-6 trans-signalling; amplifies inflammatory gene expression (IL-8, ICAM-1, VCAM-1)
- leptin β IL-6 induces hypothalamic SOCS3 creating leptin resistance; contributes to obesity-related hyperphagia
- SOCS3 β IL-6-induced suppressor of cytokine signaling; creates negative feedback loop; also blocks insulin and leptin signaling
- Specialized pro-resolving mediators (SPMs) β RvD1, RvE1, MaR1 actively resolve IL-6-driven inflammation; promote macrophage efferocytosis
- Cortisol β IL-6 activates HPA axis; cortisol provides negative feedback on IL-6 production; cortisol resistance perpetuates IL-6 elevation
- Low-Grade Inflammation β chronic IL-6 elevation (>3 pg/mL) is defining feature of metaflammation in metabolic diseases
ΒΆ Module References
- Module 1
- Module 4
- Module 10